The ACTN3 R577X variant — known as the “sprint gene” — determines your muscle fiber type composition, shaping how your body builds power, recovers from training, and responds to growth hormone axis pathways. The Precision Peptide Genetic Test includes ACTN3 as one of 15 Muscle Growth insights across 14 pathways, 49 peptides, and 150+ genetic insights.

The Precision Peptide Genetic Test analyzes 15 muscle growth insights — ACTN3, IGF1, MSTN, GHSR, and GHR — within a panel of 14 pathways, 49 peptides, and 150+ genetic insights. This pillar guide breaks down each muscle gene, what it reveals about fiber type and growth response, and why your DNA is the most underused variable in any muscle protocol.

Peptide protocols fail many people not because the science is wrong, but because they're built for population averages. FTO, FOXO3, ACTN3, SHBG, and COMT variants mean weight management, longevity, muscle, and hormone biology works differently in everyone. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights to reveal exactly where your biology diverges.

The Precision Peptide Genetic Test analyzes your genetic response to the pathways targeted by 49 unique compounds across five protocol families — GLP-1, growth hormone, androgens, estrogens, and vascular modulators. This post breaks down how each protocol family maps to genetic pathways, what the 49-peptide panel covers, and what your results reveal.

Genetic testing reveals tendencies, not outcomes — a FOXO3 variant doesn't predict lifespan, a slow-COMT variant doesn't diagnose any condition, an ACTN3 XX genotype doesn't cap muscle growth. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights. Understanding what DNA can and cannot tell you is the difference between informed and overconfident.

Your Precision Peptide Genetic Test report delivers 150+ insights across 14 pathways — FOXO3 for longevity, ACTN3 for muscle, COMT for methylation, and more. This guide walks through how to read pathway scores, interpret gene variants, and synthesize findings into the informed conversation every peptide protocol decision should start with.

Before committing to a peptide protocol, genetic testing reveals how your body will actually respond across GLP-1 signaling, growth hormone axis, estrogen clearance, and sexual response pathways. The Precision Peptide Genetic Test maps 14 pathways, 49 peptides, and 150+ genetic insights. Test first. Invest second. That sequence is the entire premise of precision peptide decisions.

Genetic peptide testing analyzes how your DNA shapes 14 biological pathways that peptide protocols target — from GLP-1 signaling to growth hormone axis to estrogen clearance. The PlexusDx Precision Peptide Genetic Test delivers 150+ insights across 49 unique peptides, turning peptide decisions from guesswork into evidence-based conversations with your healthcare provider.

The Precision Peptide Genetic Test processes raw DNA through Illumina Global Screening Array genotyping, CLIA-certified lab analysis, and AI-driven pathway interpretation — transforming 57 SNPs across 48 genes into 150+ actionable insights spanning 14 pathways and 49 peptides. This post explains how that pipeline works end to end, from saliva sample to personalized genetic report.

The PlexusDx Precision Peptide Genetic Test analyzes 17 longevity-aging genetic insights across five peptide pathways — Epitalon, FOXO4-DRI, Glutathione, Humanin, and Vilon — covering 15 SNPs across 14 genes including FOXO3, TERT, SIRT1, GPX1, and PPARGC1A. This article explains what each insight reveals and why peptide-specific longevity testing is a distinct category of genetic analysis.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

In April 2026, a Nature GWAS of 27,885 GLP-1 medication users found GIPR rs1800437 associated with outcomes specifically in tirzepatide users — not in GLP-1-only agonist users. This article explains what that finding means, why the dual-receptor distinction matters, and why the PlexusDx Precision Peptide Genetic Test directly genotypes this SNP across 34 weight management insights.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.

A Diabetes Care analysis estimates tirzepatide may reduce MACE risk by up to 28% and all-cause mortality by 39% compared to theoretical placebo — a figure the SURPASS-CVOT trial design couldn't directly show. Here's what the imputed placebo data reveals, and why GLP-1 receptor pathway genetics matter before any weight management decision.